| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2455 | 2016 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863, 2015 | 2131 | 2015 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1578 | 2015 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1572 | 2016 |
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International … MA Gertz, R Comenzo, RH Falk, JP Fermand, BP Hazenberg, ... American journal of hematology 79 (4), 319-328, 2005 | 1525 | 2005 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1498 | 2015 |
| Lenalidomide maintenance after stem-cell transplantation for multiple myeloma M Attal, V Lauwers-Cances, G Marit, D Caillot, P Moreau, T Facon, ... New England Journal of Medicine 366 (19), 1782-1791, 2012 | 1385 | 2012 |
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome H Avet-Loiseau, M Attal, P Moreau, C Charbonnel, F Garban, C Hulin, ... Blood 109 (8), 3489-3495, 2007 | 1218 | 2007 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1210 | 2016 |
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... The lancet oncology 12 (5), 431-440, 2011 | 1169 | 2011 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1008 | 2013 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1006 | 2012 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 981 | 2016 |
| Heterogeneity of genomic evolution and mutational profiles in multiple myeloma N Bolli, H Avet-Loiseau, DC Wedge, P Van Loo, LB Alexandrov, ... Nature communications 5 (1), 2997, 2014 | 948 | 2014 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 929 | 2016 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 907 | 2014 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 901 | 2019 |
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 888 | 2014 |
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma M Attal, JL Harousseau, S Leyvraz, C Doyen, C Hulin, L Benboubker, ... Blood 108 (10), 3289-3294, 2006 | 870 | 2006 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 868 | 2019 |
